Advancing CAR-NK Cell Therapies
Cartherics Pty Ltd, a biotechnology company in Melbourne, Australia, and Catalent, Inc., based in Tampa, FL, have announced an expansion of their commercial licence agreement. This partnership aims to enhance the development of off-the-shelf immune cell therapies for women’s diseases, notably ovarian cancer and endometriosis.
Cartherics focuses on developing iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. Catalent is a leader in enabling better treatment development and supply globally. The expanded agreement allows Cartherics to utilise Catalent’s cGMP-compliant induced pluripotent stem cells line for manufacturing and commercialization purposes.
Dr. Ian Nisbet, CEO of Cartherics, expressed enthusiasm about the collaboration, stating, “We are delighted to have established a collaborative relationship with Catalent, a leading cell and gene therapy CDMO, to expedite the development of our CAR-NK cell products.” The partnership is viewed as a strategic move to support Cartherics’ mission to develop cost-effective therapies for cancer and other diseases.
Meanwhile, David McErlane, Biologics Group President for Catalent, commented on the partnership, “We are thrilled to broaden our partnership with Cartherics and support the important work the company is doing to develop Natural Killer cells for the treatment of cancer.” He highlighted the engagement of their teams in achieving positive outcomes at all stages of development.
Under the terms of the agreement, Cartherics has the rights to develop and commercialise multiple product candidates derived from Catalent’s off-the-shelf cGMP iPSC line. This includes their lead CAR-NK cell product, CTH-401. The licenced iPSC line is part of a broader portfolio of clinical-grade iPSC lines, which have undergone stringent quality control processes.
FDA Approval and Manufacturing
Cartherics has already gained approval from the U.S. Food and Drug Administration (FDA) for using the licenced iPSC line to generate CTH-401. The companies have demonstrated full compatibility between CTH-401 and Catalent’s iPSC-NK manufacturing platform, which significantly advances their collaborative efforts.
The agreement outlines provisions for Cartherics to use Catalent as its contract manufacturing organisation for late-stage clinical trials and commercial supply. Importantly, Cartherics retains the ability to manufacture their clinical trial materials and has the option to participate in downstream manufacturing as the partnership progresses.
This enhanced partnership provides a robust framework for collaboration, ensuring both companies can advance their shared goal of bringing effective treatments to market. As a result, the collaboration marks a significant step forward in delivering innovative therapies to patients worldwide.
Last updated: 29 June 2026, 12:30 pm
